Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of HKI in second or later recurrent/progressive glioblastoma
CTR20240113Phase 2Active
- Sponsor
- Chengdu Jinruijiye Biotechnology
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of honokiol liposome for injection in glioblastoma (GBM), sponsored by Chengdu Jinruijiye Biotechnology. Started Feb 2025; status: active.
02
Drugs
honokiol liposome for injection
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20240113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240113.